Phase 2 study evaluating biomarker-driven low-dose NIvolumab and Immune-Sensitizing Radiotherapy in locally advanced resectable GAstroesophageal junction/GAstric cancers (NISaRGA) (ESMO Asia 2026) - Oct 1, 2026 - Abstract #1081TiP; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Biomarker • Metastases • P2 data • Gastric Cancer • Oncology • Solid Tumor
|
|
Anuradha Mehta; Anant Ramaswamy; Vikas S. Ostwal; Prabhat G. Bhargava; Rahul Krishnatry; George John; Vikram Chaudhari; Shailesh Shrikhande; Munita Bal; Rajiv K. Kaushal; Ameya Puranik; Reena Engineer; Subhash Yadav; Omshree Shetty; Akshay Baheti; Manish Bhandare; Shivakumar Gudi; Suman Kumar Ankathi
|